{"nctId":"NCT00652951","briefTitle":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","startDateStruct":{"date":"2008-04-01","type":"ACTUAL"},"conditions":["Infections, Streptococcal"],"count":780,"armGroups":[{"label":"Synflorix + Infanrix hexa Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)","Biological: Infanrix™ hexa."]},{"label":"Synflorix + Pediacel Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)","Biological: Pediacel™"]},{"label":"Prevenar + Pediacel Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Pediacel™","Biological: Prevenar™"]}],"interventions":[{"name":"GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)","otherNames":[]},{"name":"Infanrix™ hexa.","otherNames":[]},{"name":"Pediacel™","otherNames":[]},{"name":"Prevenar™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardian(s) can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.\n* A male or female between, and including, 6-12 weeks (42-90 days) of age at the time of the first vaccination.\n* Written informed consent obtained from both parents or from the guardian(s) of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n* Born after a gestation period of at least 36 weeks.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the entire study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.\n* Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting from one month (30 days) before and up to one month (30 days) after each dose of study vaccine.\n* Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae.\n* Children for whom hepatitis B vaccination is required according to the local recommendations\n* History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b disease.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* History of any neurologic disorders or seizures.\n* Acute disease at the time of enrolment.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination\n* A family history of congenital or hereditary immunodeficiency.\n* Major congenital defects or serious chronic illness.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary Vaccination","description":"Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were measured by 22F-inhibition Enzyme-Linked ImmunSorbent Assay (ELISA); presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was greater than or equal to (≥) 0.05 μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":null},{"groupId":"OG001","value":"1.31","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":null},{"groupId":"OG001","value":"1.59","spread":null},{"groupId":"OG002","value":"2.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":null},{"groupId":"OG001","value":"2.16","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.35","spread":null},{"groupId":"OG002","value":"0.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"1.77","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.47","spread":null},{"groupId":"OG002","value":"2.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.38","spread":null},{"groupId":"OG001","value":"3.33","spread":null},{"groupId":"OG002","value":"3.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":null},{"groupId":"OG001","value":"1.07","spread":null},{"groupId":"OG002","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":null},{"groupId":"OG001","value":"1.96","spread":null},{"groupId":"OG002","value":"3.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.54","spread":null},{"groupId":"OG002","value":"1.24","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Concentration Against Protein D (PD) - Primary Vaccination","description":"Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1580","spread":null},{"groupId":"OG001","value":"1743","spread":null},{"groupId":"OG002","value":"69.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 μg/mL - Primary Vaccination","description":"Antibody concentrations against the pneumococcal serotypes were assessed by 22F-inhibition ELISA. The reference cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.02 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"176","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"180","spread":null},{"groupId":"OG002","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"179","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"186","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"181","spread":null},{"groupId":"OG002","value":"184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"187","spread":null},{"groupId":"OG002","value":"192","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"178","spread":null},{"groupId":"OG002","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"174","spread":null},{"groupId":"OG002","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"171","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - Primary Vaccination","description":"Titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off value of 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null},{"groupId":"OG001","value":"20.8","spread":null},{"groupId":"OG002","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"592.9","spread":null},{"groupId":"OG001","value":"600.4","spread":null},{"groupId":"OG002","value":"838.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"60.1","spread":null},{"groupId":"OG002","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"261.3","spread":null},{"groupId":"OG001","value":"296.4","spread":null},{"groupId":"OG002","value":"633","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2063.3","spread":null},{"groupId":"OG001","value":"2136.1","spread":null},{"groupId":"OG002","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"863.6","spread":null},{"groupId":"OG001","value":"1277.7","spread":null},{"groupId":"OG002","value":"1194","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"990.4","spread":null},{"groupId":"OG001","value":"1086.4","spread":null},{"groupId":"OG002","value":"1373.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.6","spread":null},{"groupId":"OG001","value":"84.2","spread":null},{"groupId":"OG002","value":"213.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"143.8","spread":null},{"groupId":"OG002","value":"39.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"847.4","spread":null},{"groupId":"OG001","value":"1089","spread":null},{"groupId":"OG002","value":"3703.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 μg/mL - Primary Vaccination.","description":"Antibody concentrations against the cross- reactive pneumococcal serotypes were assessed by 22F-inhibition ELISA. The reference cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.02 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A (Anti-6A and 19A) - Primary Vaccination","description":"Anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations (Anti-6A and -19A) were measured by 22F-inhibition ELISA; presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.1","spread":null},{"groupId":"OG002","value":"0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.09","spread":null},{"groupId":"OG002","value":"0.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Cross-reactive Serotypes 6A and 19A - Primary Vaccination.","description":"Titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":null},{"groupId":"OG001","value":"25.4","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"4.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Diphtheria and Tetanus Toxoids (Anti-D and T) - Primary Vaccination","description":"Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). The seropositivity cut-off value was greater than or equal to (≥) 0.1 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.475","spread":null},{"groupId":"OG001","value":"1.078","spread":null},{"groupId":"OG002","value":"1.077","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.873","spread":null},{"groupId":"OG001","value":"1.702","spread":null},{"groupId":"OG002","value":"0.934","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations - Primary Vaccination","description":"Anti-PRP antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL). The seropositivity cut-off value was ≥ 0.15 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.139","spread":null},{"groupId":"OG001","value":"4.796","spread":null},{"groupId":"OG002","value":"2.219","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations - Primary Vaccination","description":"Anti-PT, anti-FHA and anti-PRN antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off value was ≥ 5 EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":null},{"groupId":"OG001","value":"36.4","spread":null},{"groupId":"OG002","value":"40.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.6","spread":null},{"groupId":"OG001","value":"100.8","spread":null},{"groupId":"OG002","value":"100.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"40.1","spread":null},{"groupId":"OG002","value":"45.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations - Primary Vaccination.","description":"Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). A seroprotected subject was a subject whose antibody ChemiLuminescence ImmunoAssay (CLIA) concentration was greater than or equal to the cut-off value ≥ 10 milli-international units per milliliter (mIU/mL). Note: investigations on the quality of some serology assays revealed that the anti-HBs ELISA overestimated concentration between 10-100 mIU/mL while values \\> 100 mIU/mL were confirmed valid. Therefore, all available samples at one month post-dose III and one month post-dose IV timepoints for which the anti-HBs antibody concentration was between 10-100 mIU/mL by in-house ELISA, were retested by the commercial assay Centaur™, an FDA-approved and CE-marked CLIA with a cut-off defining seropositivity of 6.2 mIU/mL. Anti-HBs seroprotection was redefined as in-house ELISA concentration \\> 100 mIU/mL or CLIA concentration \\> 10 mIU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"356.9","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"11.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polio Types 1, 2 and 3 Titers - Primary Vaccination.","description":"Anti-polio 1, -polio 2, -polio 3 antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off value ≥ 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"18.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.1","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"23.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":null},{"groupId":"OG001","value":"34.2","spread":null},{"groupId":"OG002","value":"26.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 μg/mL - Booster Vaccination","description":"Antibody concentrations against the pneumococcal serotypes were assessed by 22F-inhibition ELISA. The reference cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.02 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"152","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"127","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"164","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"168","spread":null},{"groupId":"OG002","value":"176","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"172","spread":null},{"groupId":"OG002","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"143","spread":null},{"groupId":"OG002","value":"151","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"157","spread":null},{"groupId":"OG002","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"195","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"194","spread":null},{"groupId":"OG002","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"191","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"181","spread":null},{"groupId":"OG002","value":"192","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"198","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"197","spread":null},{"groupId":"OG002","value":"202","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"197","spread":null},{"groupId":"OG002","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"196","spread":null},{"groupId":"OG002","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"191","spread":null},{"groupId":"OG002","value":"196","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"190","spread":null},{"groupId":"OG002","value":"194","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) - Booster Vaccination","description":"Anti-pneumococcal serotype 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations were assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off value was ≥ 0.05 μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.22","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":null},{"groupId":"OG001","value":"0.43","spread":null},{"groupId":"OG002","value":"0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":null},{"groupId":"OG001","value":"0.42","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.32","spread":null},{"groupId":"OG002","value":"0.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.62","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":null},{"groupId":"OG001","value":"0.76","spread":null},{"groupId":"OG002","value":"0.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":null},{"groupId":"OG001","value":"1.14","spread":null},{"groupId":"OG002","value":"1.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":null},{"groupId":"OG001","value":"0.43","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"0.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.38","spread":null},{"groupId":"OG002","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":null},{"groupId":"OG001","value":"2.5","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.04","spread":null},{"groupId":"OG001","value":"3.29","spread":null},{"groupId":"OG002","value":"4.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.27","spread":null},{"groupId":"OG001","value":"3.27","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":null},{"groupId":"OG001","value":"1.41","spread":null},{"groupId":"OG002","value":"2.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.79","spread":null},{"groupId":"OG001","value":"4.06","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.96","spread":null},{"groupId":"OG001","value":"4.23","spread":null},{"groupId":"OG002","value":"6.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.59","spread":null},{"groupId":"OG001","value":"4.95","spread":null},{"groupId":"OG002","value":"7.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.36","spread":null},{"groupId":"OG001","value":"4.63","spread":null},{"groupId":"OG002","value":"5.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.45","spread":null},{"groupId":"OG001","value":"5.8","spread":null},{"groupId":"OG002","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.32","spread":null},{"groupId":"OG001","value":"2.6","spread":null},{"groupId":"OG002","value":"5.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - Booster Vaccination","description":"Titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off value of 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"5.6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"15.3","spread":null},{"groupId":"OG002","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"96.7","spread":null},{"groupId":"OG002","value":"27.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"818.9","spread":null},{"groupId":"OG001","value":"754.3","spread":null},{"groupId":"OG002","value":"138.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"267.2","spread":null},{"groupId":"OG001","value":"338.7","spread":null},{"groupId":"OG002","value":"149.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117.3","spread":null},{"groupId":"OG001","value":"142.5","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"6.8","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"15.4","spread":null},{"groupId":"OG002","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"314.1","spread":null},{"groupId":"OG001","value":"350.4","spread":null},{"groupId":"OG002","value":"338.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"208.8","spread":null},{"groupId":"OG001","value":"221.4","spread":null},{"groupId":"OG002","value":"4.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1046.8","spread":null},{"groupId":"OG001","value":"1121.6","spread":null},{"groupId":"OG002","value":"2335.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.3","spread":null},{"groupId":"OG001","value":"132.4","spread":null},{"groupId":"OG002","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"681.4","spread":null},{"groupId":"OG001","value":"763.3","spread":null},{"groupId":"OG002","value":"1807.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3936.5","spread":null},{"groupId":"OG001","value":"3976","spread":null},{"groupId":"OG002","value":"129.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2512.9","spread":null},{"groupId":"OG001","value":"2257.6","spread":null},{"groupId":"OG002","value":"3889.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1534.2","spread":null},{"groupId":"OG001","value":"1896.3","spread":null},{"groupId":"OG002","value":"1867.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"720.7","spread":null},{"groupId":"OG001","value":"385.9","spread":null},{"groupId":"OG002","value":"660.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"435.7","spread":null},{"groupId":"OG001","value":"475.4","spread":null},{"groupId":"OG002","value":"123.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2895.4","spread":null},{"groupId":"OG001","value":"2895.3","spread":null},{"groupId":"OG002","value":"12418.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 μg/mL - Booster Vaccination.","description":"Antibody concentrations against the cross-reactive pneumococcal serotypes were assessed by 22F-inhibition ELISA. The reference cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.02 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A (Anti-6A and 19A) - Booster Vaccination","description":"Anti-pneumococcal cross-reactive serotype 6A and 19A antibody concentrations were assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off value was ≥ 0.05 μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.11","spread":null},{"groupId":"OG002","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":null},{"groupId":"OG001","value":"0.12","spread":null},{"groupId":"OG002","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null},{"groupId":"OG001","value":"0.49","spread":null},{"groupId":"OG002","value":"0.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.52","spread":null},{"groupId":"OG002","value":"0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Cross-reactive Serotypes 6A and 19A - Booster Vaccination.","description":"Titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off value of 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"30.7","spread":null},{"groupId":"OG002","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"5.5","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143.3","spread":null},{"groupId":"OG001","value":"197.1","spread":null},{"groupId":"OG002","value":"493.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":null},{"groupId":"OG001","value":"24.6","spread":null},{"groupId":"OG002","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Protein D (Anti-PD) - Booster Vaccination.","description":"Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"421","spread":null},{"groupId":"OG001","value":"520.5","spread":null},{"groupId":"OG002","value":"80.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1715","spread":null},{"groupId":"OG001","value":"1936.8","spread":null},{"groupId":"OG002","value":"84.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Diphtheria and Tetanus Toxoids (Anti-D and T) - Booster Vaccination.","description":"Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). The seropositivity cut-off value was greater than or equal to (≥) 0.1 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.235","spread":null},{"groupId":"OG001","value":"0.232","spread":null},{"groupId":"OG002","value":"0.266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.728","spread":null},{"groupId":"OG001","value":"0.536","spread":null},{"groupId":"OG002","value":"0.232","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.061","spread":null},{"groupId":"OG001","value":"3.226","spread":null},{"groupId":"OG002","value":"4.882","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.628","spread":null},{"groupId":"OG001","value":"5.989","spread":null},{"groupId":"OG002","value":"3.248","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations - Booster Vaccination","description":"Anti-PRP antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL). The seropositivity cut-off value was ≥ 0.15 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.475","spread":null},{"groupId":"OG001","value":"0.855","spread":null},{"groupId":"OG002","value":"0.371","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.331","spread":null},{"groupId":"OG001","value":"39.383","spread":null},{"groupId":"OG002","value":"23.676","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations - Booster Vaccination.","description":"Anti-PT, anti-FHA and anti-PRN antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off value was ≥ 5 EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"35.3","spread":null},{"groupId":"OG002","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"6.8","spread":null},{"groupId":"OG002","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null},{"groupId":"OG001","value":"47.4","spread":null},{"groupId":"OG002","value":"54.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"343.5","spread":null},{"groupId":"OG001","value":"135.7","spread":null},{"groupId":"OG002","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"281.7","spread":null},{"groupId":"OG001","value":"97.8","spread":null},{"groupId":"OG002","value":"106.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations - Booster Vaccination.","description":"Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). A seroprotected subject was a subject whose antibody ChemiLuminescence ImmunoAssay (CLIA) concentration was greater than or equal to the cut-off value ≥ 10 milli-international units per milliliter (mIU/mL). Note: investigations on the quality of some serology assays revealed that the anti-HBs ELISA overestimated concentration between 10-100 mIU/mL while values \\> 100 mIU/mL were confirmed valid. Therefore, all available samples at one month post-dose III and one month post-dose IV timepoints for which the anti-HBs antibody concentration was between 10-100 mIU/mL by in-house ELISA, were retested by the commercial assay Centaur™, an FDA-approved and CE-marked CLIA with a cut-off defining seropositivity of 6.2 mIU/mL. Anti-HBs seroprotection was redefined as in-house ELISA concentration \\> 100 mIU/mL or CLIA concentration \\> 10 mIU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142.1","spread":null},{"groupId":"OG001","value":"9.9","spread":null},{"groupId":"OG002","value":"9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1981","spread":null},{"groupId":"OG001","value":"8.6","spread":null},{"groupId":"OG002","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polio Types 1, 2 and 3 Titers - Booster Vaccination.","description":"Anti-polio 1, -polio 2, -polio 3 antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off value ≥ 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"7.3","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"10.6","spread":null},{"groupId":"OG002","value":"10.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"8.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"370.7","spread":null},{"groupId":"OG001","value":"177.5","spread":null},{"groupId":"OG002","value":"221.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"710.8","spread":null},{"groupId":"OG001","value":"338.8","spread":null},{"groupId":"OG002","value":"481.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"631.5","spread":null},{"groupId":"OG001","value":"311.9","spread":null},{"groupId":"OG002","value":"348.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Booster Vaccine Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antibodies - Booster Vaccination.","description":"A booster responder to PT/FHA/PRN was defined as a subject with antibodies concentration ≥ 5 EL.U/mL against PT/FHA/PRN in subjects who were initially seronegative for anti-PT/FHA/PRN antibodies (i.e., subjects with anti-PT/FHA/PRN antibody concentrations \\< 5 EL.U/mL), or antibody concentration ≥ 2 fold the pre-vaccination antibody concentration in subjects who were initially seropositive (i.e., subjects with anti-PT/FHA/PRN antibody concentrations ≥ 5 EL.U/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 μg/mL - 12 Months After Booster Dose.","description":"Antibody concentrations against the pneumococcal serotypes were assessed by 22F-inhibition ELISA. The reference cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.02 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"102","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"129","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"157","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"157","spread":null},{"groupId":"OG002","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"156","spread":null},{"groupId":"OG002","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"155","spread":null},{"groupId":"OG002","value":"161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"158","spread":null},{"groupId":"OG002","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"126","spread":null},{"groupId":"OG002","value":"153","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) - 12 Months After Booster Dose.","description":"Anti-pneumococcal serotype 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations were assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off value was ≥ 0.05 μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.32","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null},{"groupId":"OG001","value":"0.29","spread":null},{"groupId":"OG002","value":"0.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null},{"groupId":"OG001","value":"0.47","spread":null},{"groupId":"OG002","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.32","spread":null},{"groupId":"OG002","value":"0.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null},{"groupId":"OG001","value":"0.73","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":null},{"groupId":"OG001","value":"0.78","spread":null},{"groupId":"OG002","value":"0.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null},{"groupId":"OG001","value":"0.85","spread":null},{"groupId":"OG002","value":"1.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null},{"groupId":"OG001","value":"0.64","spread":null},{"groupId":"OG002","value":"1.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":null},{"groupId":"OG001","value":"1.46","spread":null},{"groupId":"OG002","value":"1.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":null},{"groupId":"OG001","value":"0.52","spread":null},{"groupId":"OG002","value":"1.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - 12 Months After Booster Dose.","description":"Titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off value of 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"9.9","spread":null},{"groupId":"OG002","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15.5","spread":null},{"groupId":"OG002","value":"45.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"13.7","spread":null},{"groupId":"OG002","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":null},{"groupId":"OG001","value":"137.6","spread":null},{"groupId":"OG002","value":"220","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1982.9","spread":null},{"groupId":"OG001","value":"2205.6","spread":null},{"groupId":"OG002","value":"738.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"465.9","spread":null},{"groupId":"OG001","value":"470","spread":null},{"groupId":"OG002","value":"476.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"151.6","spread":null},{"groupId":"OG002","value":"238.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"15.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null},{"groupId":"OG001","value":"32.9","spread":null},{"groupId":"OG002","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"366.5","spread":null},{"groupId":"OG001","value":"706.1","spread":null},{"groupId":"OG002","value":"3879.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 μg/mL - 12 Months After Booster Dose.","description":"Antibody concentrations against the cross-reactive pneumococcal serotypes were assessed by 22F-inhibition ELISA. The reference cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.02 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A (Anti-6A and 19A) - 12 Months After Booster Dose.","description":"Anti-pneumococcal cross-reactive serotype 6A and 19A antibody concentrations were assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off value was ≥ 0.05 μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.15","spread":null},{"groupId":"OG002","value":"0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":null},{"groupId":"OG001","value":"0.29","spread":null},{"groupId":"OG002","value":"0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Cross-reactive Serotypes 6A and 19A - 12 Months After Booster Dose.","description":"Titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off value of 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"24.8","spread":null},{"groupId":"OG002","value":"56.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"9.1","spread":null},{"groupId":"OG002","value":"9.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Protein D (Anti-PD) - 12 Months After Booster Dose.","description":"Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"332","spread":null},{"groupId":"OG001","value":"423","spread":null},{"groupId":"OG002","value":"81.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Positive Cultures of Haemophilus Influenzae and/or Streptococcus Pneumoniae in the Nasopharynx - Primary Vaccination.","description":"Positive cultures of H. influenzae\\* (HI) and S. pneumoniae (SP) identified in the nasopharynx at each swab time point: one month post-Dose III (M3), M9 (11-13 months of age), M12 (14-16 months of age), M16 (18-20 months of age) and M21 (23-25 months of age). \\*Data presented only include results from samples confirmed as positive for H. influenzae / Non-typeable H. influenzae after differentiation from H. haemolyticus by Polymerase Chain Reaction (PCR) assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"134","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"135","spread":null},{"groupId":"OG002","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"155","spread":null},{"groupId":"OG002","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"160","spread":null},{"groupId":"OG002","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"169","spread":null},{"groupId":"OG002","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"192","spread":null},{"groupId":"OG002","value":"177","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Positive Cultures of Streptococcus Pneumoniae Vaccine Seroptypes (VS), Cross-reactive Serotypes (CRS) or Other Serotypes (OS) in the Nasopharynx - Primary Vaccination.","description":"Positive cultures of S. pneumoniae (SP) identified in the nasopharynx at each swab time point: one month post-Dose III (M3), pre-booster vaccination (11-13 months of age), M12 (14-16 months of age), M16 (18-20 months of age) and M21 (23-25 months of age).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Acquisition of New Streptococcus Pneumoniae and Haemophilus Influenzae Strains Identified in Nasopharyngeal Swabs - Primary Vaccination.","description":"Acquisition of new H. influenzae\\* (HI) and S. pneumoniae (SP) strains, identified in the nasopharynx at each swab time point: pre-booster vaccination (11-13 months of age), M12 (14-16 months of age), M16 (18-20 months of age) and M21 (23-25 months of age). \\*Data presented only include results from samples confirmed as positive for H. influenzae / Non-typeable H. influenzae after differentiation from H. haemolyticus by Polymerase Chain Reaction (PCR) assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Acquisition of New Streptococcus Pneumoniae Vaccine Serotypes (VS), Cross-reactive Serotypes (CRS) or Other Serotypes (OS) Identified in Nasopharyngeal Swabs - Primary Vaccination.","description":"Acquisition of new S. pneumonia (SP) strains, identified in the nasopharynx at each swab time point: pre-booster vaccination (11-13 months of age), M12 (14-16 months of age), M16 (18-20 months of age) and M21 (23-25 months of age).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited Local Symptoms - Primary Vaccination","description":"Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any occurrence of the specified symptom regardless of intensity. Grade 3 pain was defined as cried when limb was moved/spontaneously painful. Grade 3 redness/swelling was defined as redness/swelling spreading beyond (\\>) 30 millimeters from injection site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"159","spread":null},{"groupId":"OG002","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"134","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"135","spread":null},{"groupId":"OG002","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"193","spread":null},{"groupId":"OG002","value":"178","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"193","spread":null},{"groupId":"OG002","value":"184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"199","spread":null},{"groupId":"OG002","value":"179","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited General Symptoms - Primary Vaccination","description":"Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Any was defined as incidence of the specified symptom regardless of intensity. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. Related symptom was defined as a general symptom assessed by the investigator as causally related to study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"171","spread":null},{"groupId":"OG002","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"171","spread":null},{"groupId":"OG002","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"185","spread":null},{"groupId":"OG002","value":"180","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":null},{"groupId":"OG001","value":"182","spread":null},{"groupId":"OG002","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"176","spread":null},{"groupId":"OG002","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"172","spread":null},{"groupId":"OG002","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"111","spread":null},{"groupId":"OG002","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"137","spread":null},{"groupId":"OG002","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"220","spread":null},{"groupId":"OG002","value":"215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"219","spread":null},{"groupId":"OG002","value":"213","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"124","spread":null},{"groupId":"OG002","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null},{"groupId":"OG001","value":"230","spread":null},{"groupId":"OG002","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"238","spread":null},{"groupId":"OG001","value":"227","spread":null},{"groupId":"OG002","value":"232","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"148","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs) - Primary Vaccination.","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. \"Any\" is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"177","spread":null},{"groupId":"OG002","value":"185","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited Local Symptoms -Booster Vaccination","description":"Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any occurrence of the specified symptom regardless of intensity. Grade 3 pain was defined as cried when limb was moved/spontaneously painful. Grade 3 redness/swelling was defined as redness/swelling \\> 30 millimeters from injection site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"161","spread":null},{"groupId":"OG002","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"180","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited General Symptoms - Booster Vaccination.","description":"Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Any was defined as incidence of the specified symptom regardless of intensity. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. Related symptom was defined as a general symptom assessed by the investigator as causally related to study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"110","spread":null},{"groupId":"OG002","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"161","spread":null},{"groupId":"OG002","value":"166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs) - Booster Vaccination.","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. \"Any\" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"105","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":260},"commonTop":["Irritability","Somnolence","Erythema","Swelling","Pain"]}}}